Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It makes me hungry
IIROC Trade Resumption - IN
PRNewswire
May 24, 2017 1:17pm Comments
VANCOUVER, May 24, 2017 /CNW/ - Trading resumes in:
Company: InMed Pharmaceuticals Inc
CSE Symbol: IN
Resumption (ET): 1:45 PM
IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.
SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions
I dont know but i hope a partnership news for this patent
''Additionally, this novel, proprietary delivery system for ophthalmic drugs may also play an important role in enabling other companies’ proprietary ophthalmic drug candidates or re-invigorating the commercial potential of off-patent products that would benefit from a once-a-day dosing regimen. InMed plans to initiate discussion with potential partners to this end.''
why its so long to put a news out? They are writing it? lol
Exactly I'm verry happy with this news for the future
I think it's very positive. Inmed now has the resources in preparation with its two Phase 1 clinical trials
InMed Pharmaceuticals : Announces Pricing of $5,004,000 Underwritten Financing
share with twitter share with LinkedIn share with facebook share via e-mail
0
05/23/2017 | 04:39pm EDT
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
VANCOUVER, May 23, 2017 /CNW/ - InMed Pharmaceuticals, Inc. ("InMed" or the "Company") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce that, in connection with its proposed public offering announced on April 21, 2017, it has entered into an underwriting agreement (the "Underwriting Agreement") with a syndicate of underwriters led by Canaccord Genuity Corp. and including Eight Capital along with Roth Capital Partners, LLC serving as placement agent for sales of Units in the United States (collectively, the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, on an underwritten basis, 11,120,000 Units of the Company (the "Units") at a price of $0.45 per Unit (the "Offering Price"), for aggregate gross proceeds of $5,000,400 (the "Offering"). Each Unit will consist of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant"). Each Warrant will have an exercise price of $0.65 per common share and will be exercisable for a period of 24 months following the closing date. The Warrants will only be exercisable on a net cashless basis on the five-day volume-weighted average trading price of the common shares of the Company on the Canadian Securities Exchange ending on the date immediately preceding the date of exercise.
In addition, the Company has granted the Underwriters an option (the "Over-Allotment Option"), to purchase up to 1,668,000 additional Units at the Offering Price for a period of up to 30 days after the closing date of the Offering. In the event that the Over-Allotment Option is exercised in its entirety, the aggregate gross proceeds of the Offering to the Company will be $5,754,600.
InMed intends to use the net proceeds from the Offering for the following purposes: to support the continued research and development of INM-750 for the treatment of Epidermolysis Bullosa; to further develop the Company's other research and development programs including its biosynthesis assets; for general and administrative expenses of the Company; and to fund working capital.
Closing of the Offering is expected to occur on or about May 30, 2017, subject to the receipt of all necessary regulatory approvals and other customary closing conditions for transactions of this nature.
InMed intends to file a final short form prospectus for the Offering (the "Final Prospectus") on or about May 24, 2017 in the provinces of British Columbia, Alberta and Ontario. A copy of the Final Prospectus and the Underwriting Agreement will be available for review under the Company's profile on SEDAR at www.sedar.com.
This news release shall not constitute an offer to sell or a solicitation of any offer to buy any of the securities being offered nor shall there be any sale of any of the securities being offered in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and such securities may not be offered or sold within the United States absent registration under the U.S. Securities Act or an applicable exemption from the registration requirements thereunder.
About InMed
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
the big block on the ask is gone!!
Announcement comming!
This technology seems perfect for youtubers / influencers to add clickable links to products to sell or links to sponsors
May 10, 2017 - 11:16 PM EDT
Print
Email Article
Font Down
Font Up
Charts
EXMT 0,0011 -0,000189
Auj. 5j 1m 3m 1a 5a 10a
ICBU 0,0025 0,00
Auj. 5j 1m 3m 1a 5a 10a
iMD Companies, Inc. (ICBU) In Negotiation with Public Company for Buyout of iMD Meds, Hydroponics, CBD, and Hemp Energy Protein Bar Division
PLACERVILLE, CA, May 10, 2017 /PRNewswire/ - iMD Companies, Inc. (OTC: ICBU) Board of Directors announced today that the company has received an offer from a public company to buyout iMD Meds and all other Hydroponics, CBD products including their Hemp Energy Protein Bars. The company is currently negotiating the terms of the agreement and plans to announce the finalization of the deal. The company is looking to streamline its efforts and focus solely on being a mining company. The company feels more comfortable in registering with the SEC as a Mining company and feels the registration will be clearer for auditors and regulators.
The company completed its acquisition of Krishna Minerals back in October 2016. Krishna Minerals is a producing mine in India with over 600 acres of mining claims, which are producing manganese and Iron ore metals. Krishna Minerals has major contracts with the Chinese government to supply manganese and Iron ore to China. Krishna Minerals has received several new contracts and recently received a 66-million-dollar contract for 100,000 Metric Tons of Magnesia Chrome Powder. Because of this increased demand in mining contracts, the company feels it should focus all its efforts into mining. The company is also planning a name change to better reflect a mining company.
Richard Wilson CEO of ICBU stated, "We are excited about this buyout offer to acquire all of our Hydroponics and CBD related products including our Hemp protein bars. We feel this offer will bring substantial assets into the company. When the buyout is completed it will give IMD Companies Inc., the opportunity to focus all its efforts on mining."
Profit taking is over. now we will go up fast
Im back in today for the next ride up!
thanks. Good things ahead!!
exact, we can finish strong
Gap closed
Great news!
ok it work now! Time to do money
Does the abattis.com website work for you this morning?
Gap to close at 0.0229
Gap up near 20% on the canadian side!!
Abattis Bioceuticals : IIROC Trade Resumption - ATT
share with twitter share with LinkedIn share with facebook share via e-mail
0
05/03/2017 | 09:39am EDT
TORONTO, May 3, 2017 /CNW/ - Trading resumes in:
Company: Abattis Bioceuticals Corp
CSE Symbol: ATT
Resumption (ET): 10:15 AM
IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.
SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions
© Canada Newswire, source Canada Newswire English
anada NewsWire
TORONTO, May 3, 2017
TORONTO, May 3, 2017 /CNW/ - The following issues have been halted by IIROC:
Company: Abattis Bioceuticals Corp.
CSE Symbol: ATT
Reason: Pending News
Halt Time (ET): 7:46 AM
IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.
SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions
image: https://rt.newswire.ca/rt.gif?NewsItemId=C3614&Transmission_Id=201705030759CANADANWCANADAPR_C3614&DateId=20170503
View original content: http://www.newswire.ca/en/releases/archive/May2017/03/c3614.html
Read more at http://www.stockhouse.com/news/press-releases/2017/05/03/iiroc-trading-halt-att#U3JJIOgPk725RPHK.99
the stock is HALT this morning... NEWS
"Because we intend to lead and not simply follow the interactive video revolution, we've begun testing a soon to be released platform to expand beyond CRM and bring our interactive video experience to broadcast video. Imagine watching the Olympics and being able to click on your favorite athlete's jersey and buy it, or simply see his or her recent stats, without interrupting the action on screen. This capability and more is coming and it's coming soon," continues Mr. Cutaia.
nFusz Adds Space Station Engineer to Senior Executive Team
nFusz Continues Expansion of Its Senior Management Team
HOLLYWOOD, CA -- (Marketwired) -- 05/02/17 -- nFüsz, Inc. (OTCQB: FUSZ), (formerly bBooth) the Hollywood-based digital technology company, is pleased to announce the continued expansion of its senior executive team to include notable NASA projects engineer Mohammad Amanullah, who joins nFüsz as Director of Broadcast & Government Applications and a Member of its Advisory Board. In his new role, Mr. Amanullah will lead the Company's Interactive Video Broadcast & Government product strategy and related customer acquisition initiatives.
Prior to joining nFüsz, Mr. Amanullah served as Senior Hardware Engineer for Lockheed Martin Corporation at Johnson Space Center in Houston responsible for video system design and development for NASA's Mission Control Center (MCC), including the MCCS, MCC-21 and the International Space Station (ISS). As video lead for NASA's MCC-21 and ISS programs, Mr. Amanullah redesigned the video systems and was the training coordinator for the platform engineering department.
With more than 40 year's experience, Mr. Amanullah also held senior engineering positions at Ford Aerospace Corporation, where he was responsible for systems design and development, configuration, coordination, implementation and testing of the data, audio and video transmission for the Space Shuttle Program. He also held a senior engineering position at the US Department of Treasury for the U.S. / Saudi Arabia Joint Commission.
"We're about to release notifiCRM version 3.0 of our interactive video-based CRM/Lead Gen application for sales based-organizations that seek a truly effective tool designed to help even inexperienced salespeople close deals -- not merely track and report sales activity to management," states Rory J. Cutaia, nFüsz CEO. "Because we intend to lead and not simply follow the interactive video revolution, we've begun testing a soon to be released platform to expand beyond CRM and bring our interactive video experience to broadcast video. Imagine watching the Olympics and being able to click on your favorite athlete's jersey and buy it, or simply see his or her recent stats, without interrupting the action on screen. This capability and more is coming and it's coming soon," continues Mr. Cutaia.
"To execute plans of this magnitude requires bold, experienced talent. Mohammad Amanullah knows first-hand what it takes to be the first, to accomplish that which others only dream, and we are thrilled to welcome him to our team," states Mr. Cutaia.
"I've spent my entire career at the forefront of technological innovation," states Mr. Amanullah. "And I know very well what it takes to achieve it. I am inspired by the talent, dedication, ingenuity and leadership of this company and I am thrilled to be part of the nFüsz team," states Mr. Amanullah.
GAP closed!
Gap need to be close and after that We will be able to move upwards in a healthier way
exactly